The impact of new drug introduction on drug expenditure in primary health care in Catalunya, Spain

Annals of Pharmacotherapy

Volumn 39, Issue 1, 2005, Pages 177-182

  Zara, Corinne ^a,d   Torralba, Miguel ^b   Sotoca, José M ^c   Prat, Alba ^b   Faixedas, María Teresa ^a   Gilabert, Antoni ^b  

^a C Agy Hlth Technol Assess Res   (Spain)

^b Div of Pharmaceutical Monitoring   (Spain)

^c Les Corts Primary Health Care Centre   (Spain)

^d Servei Català de la Salut   (Spain)

Author keywords

Efficacy; New drugs; Prescription

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIDIARRHEAL AGENT; ANTIGLAUCOMA AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIMIGRAINE AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; ANTIPARKINSON AGENT; ANTIPSORIASIS AGENT; ANTIRHEUMATIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIULCER AGENT; CALCIUM ANTAGONIST; CONTRAST MEDIUM; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; NEUROLEPTIC AGENT; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; SPASMOLYTIC AGENT; TRANQUILIZER; UNINDEXED DRUG;

ARTICLE; DRUG COST; DRUG UTILIZATION; PRESCRIPTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SPAIN;

DRUG APPROVAL; DRUG UTILIZATION; HEALTH EXPENDITURES; HUMANS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; SPAIN;

EID: 11144239385     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E236     Document Type: Article

References (27)

1. Lexchin J. New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials? Can Fam Physician 2002;48:1487-92.
2. Changing patterns of pharmaceutical innovation. The National Institute for Health Care Management Foundation 2002 Mayo. www.nihcm.org/innovations.pdf (accessed 2002 Dec 10).
3. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
4. Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C. Post-marketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Saf 2002;11:439-46.
5. García Lirola MA, Cabeza Barrera J, Rodríguez Espejo M, Alegre del Rey E, Rabadán Asensio A. [Adoption of new medications by prescribing physicians. The innovator physician] Spanish. Aten Primaria 2000;25:22-8.
6. Jacoby A, Smith M, Eccles M. A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs. Br J Gen Pract 2003;53:120-5.
7. aparte). Inf Ter Sist Nac Sal 2003;27:57-75.
8. Gervas J, Pérez Fernández M. Rabdomiolisis y mortalidad por cerivastatina: más allá de la seguridad. Healthy Skepticism International News. www.healthyskepticism.org (accessed 2003 Feb 27).
9. 2 agonist. www.sign.ac.uk/guidelines/published/support/ guideline63 (accessed 2003 Oct 27).
10. Salmeterol & fluticasone Accuhaler. New Product Evaluation. Trent Drug Information Services, 1999. www.ukmicentral.nhs.uk/newdrugs/reviews (accessed 2003 Nov 13).
11. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII). JAMA 2003;289:2560-72.
12. American Diabetes Association. The treatment of hypertension in adults with diabetes (position statement). Diabetes Care 2002;25(suppl 1):S71-3.
13. Clopidogrel. New product evaluation. Trent Drug Information Services, 1998. www.ukmicentral.nhs.uk/newdrugs/reviews (accessed 2003 Nov 13).
14. Clopidogrel and acute coronary syndrome. Drug Therapeut Bull 2002;40:41-2.
15. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink M, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346:1800-6.
16. Management of osteoporosis. Scottish Intercollegiate Guidelines Network. 2003. www.sign.ac.uk/pdf/sign71.pdf (accessed 2003 Oct 10).
17. Kanis JA, Brazier JE, Stevenson M, Stevenson M, Calvert NW, Lloyd Jones M. Treatment of established osteoporosis: a systematic review and cost-utility analysis. www.ncchta.org/fullmono/mon629.pdf (accessed 2003 Feb 21).
18. Melzer D. New drug treatment for Alzheimer's disease: lessons for healthcare policy. BMJ 1998;316:762-4.
19. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmina para la enfermedad de Alzheimer (Translated Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
20. Olin J, Schneider L. Galantamine for Alzheimer's disease. In: The Cochrane Library, 2003(1). Oxford: Update Software.
21. Guidelines for the use of acetylcholinesterase inhibitors in the treatment of people with Alzheimer's disease. New Zealand Guidelines Group. 2000. www.nzgg.org.nz (accessed 2003 Aug 4).
22. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. National Institute for Clinical Excellence. January 2001. www.nice.org.uk/pdf/ALZHEIMER_full_guidance.pdf (accessed 2003 Feb 20).
23. Jüni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002;324:1287-8.
24. Guidance on the use of cyclo-oxygenase (Cox II) selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. National Institute for Clinical Excellence. July 2001. www.nice.org.uk/pdf/coxiifullguidance.pdf (accessed 2002 Dec 20).
25. Jette NJ, Marson AG, Hutton JL. Topiramato como adyuvante para la epilepsia parcial resistente a medicamentos (Translated Cochrane Review). In: The Cochrane Library. Oxford: Update Software, December 2, 2003.
26. LaRoche SM, Helmers SL. The new antiepileptic drugs. Scientific review. JAMA 2004;291:605-14.
27. LaRoche SM. Helmers SL. The new antiepileptic drugs. Clinical applications. JAMA 2004;291:615-20.